Anton Egorov
-
- HER2/EGFR in Cancer Research 11
- Cancer Treatment and Pharmacology 11
- Colorectal Cancer Treatments and Studies 3
-
- Advanced Breast Cancer Therapies 7
- Lung Cancer Treatments and Mutations 3
-
- Lymphoma Diagnosis and Treatment 4
-
- Breast Cancer Treatment Studies 9
-
- Acute Lymphoblastic Leukemia research 2
- Co-authors
- Javier CortésShahid AshfaqueWěi LiSung‐Bae KimJack W. SingerGiuliano Santos BorgesFabrice AndréRuth Pettengell
- Partner nations
- FranceUnited StatesSpain
In The Last Decade
Anton Egorov
23 papers receiving 255 citations
Hit Papers
Peers
Comparison fields: 5 of 40
- Oncology 206
- Pulmonary and Respiratory Medicine 94
- Pathology and Forensic Medicine 44
- Cancer Research 31
- Radiology, Nuclear Medicine and Imaging 41
Countries citing papers authored by Anton Egorov
This map shows the geographic impact of Anton Egorov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anton Egorov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anton Egorov more than expected).
Fields of papers citing papers by Anton Egorov
This network shows the impact of papers produced by Anton Egorov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anton Egorov. The network helps show where Anton Egorov may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Anton Egorov, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 2 | |
| 3 | 2025 | 3 | |
| 4 | 2024 | 5 | |
| 5 | Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trialbreakdown → | 2024 | 53 |
| 6 | 2024 | 15 | |
| 7 | 2024 | 0 | |
| 8 | 2024 | 16 | |
| 9 | 2024 | 6 | |
| 10 | 2023 | 4 | |
| 11 | 2023 | 24 | |
| 12 | 2023 | 14 | |
| 13 | 2023 | 7 | |
| 14 | 2022 | 9 | |
| 15 | 2022 | 1 | |
| 16 | 2020 | 40 | |
| 17 | 2019 | 12 | |
| 18 | 2018 | 14 | |
| 19 | 2018 | 3 | |
| 20 | [Double-blind placebo-controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis]. | 2005 | 6 |
About Anton Egorov
Anton Egorov is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 25 papers that have together received 260 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (11 papers), Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (9 papers), Advanced Breast Cancer Therapies (7 papers), Lymphoma Diagnosis and Treatment (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Acute Lymphoblastic Leukemia research (2 papers). The work is most often cited by research in Oncology (206 citations), Pulmonary and Respiratory Medicine (94 citations) and Pathology and Forensic Medicine (44 citations). Anton Egorov has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Javier Cortés, Shahid Ashfaque, Wěi Li, Sung‐Bae Kim, Jack W. Singer, Giuliano Santos Borges, Fabrice André, Ruth Pettengell, Sara A. Hurvitz and Seock‐Ah Im. Their work appears in journals such as Nature Medicine, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.